Navigation Links
Keystone Nano Announces Progress On RNA Delivery
Date:4/11/2017

STATE COLLEGE, Pa., April 11, 2017 /PRNewswire/ -- Keystone Nano, Inc. (KN), a clinical stage biopharmaceutical company focused on improving cancer treatments through the application of nanotechnology, announced today significant progress on the delivery of RNA using NanoJackets (NJs).  KN's NanoJackets are proprietary, customizable calcium phosphate nanoparticles that protect the active agent in the bloodstream and deliver it to targeted cells.  Key recent achievements include:

  • substantial new knowledge on encapsulating various kinds of RNA including siRNA, micro RNA and messenger RNA,
  • improved knowledge about the safety/toxicity of the NanoJacketed RNA,
  • new understanding of bio-distribution after administration by injection or inhalation, and
  • greater knowledge about the length of time RNA-NanoJackets work within the body

KN is working to optimize the therapeutic activity of RNA both for the internal programs and for pharmaceutical client companies.  KN has found that working with NanoJackets to encapsulate and deliver the different types of RNA requires different approaches for each.  However, in all cases, KN's RNA-NanoJackets have shown that they contain substantial amounts of RNA, are composed of safe and well tolerated materials, protect the RNA from degradation in the blood stream and can be targeted to specific cell types.

Several new breakthrough therapies anticipate using the different types of RNA to halt disease progression – either by silencing select RNA processes associated with disease, or by using RNA to code for production of therapeutic molecules within the body itself.  The increasing interest in RNA therapy has led to a need for a safe, effective and efficient method to deliver RNA.  KN's calcium phosphate NanoJackets offer a highly biocompatible, non-toxic and effective solution to that problem.

KN's work in RNA delivery has been supported by grants from the National Cancer Institute, the National Institute for Allergies and Infectious Diseases, and the Pennsylvania Department of Health.  KN's work in RNA delivery builds on work at Penn State and the University of Virginia. Jeff Davidson, KN's CEO, noted: "our research team has made great progress building powerful new ways to deliver RNA.  Our goal is to continue this work to further improve human health."

About Keystone Nano, Inc.  KNs lead product, Ceramide NanoLiposome, entered clinical testing in early 2017.  For more information visit www.keystonenano.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/keystone-nano-announces-progress-on-rna-delivery-300437963.html


'/>"/>
SOURCE Keystone Nano, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
2. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
3. MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering
4. University City Keystone Innovation Zone Expands to Old City, N3rd Street Startup Community
5. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
6. Greater Gift Initiative Announces Partnership with INC Research
7. Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
8. Bioptix Announces Executive Leadership Change
9. Nerium International announces expansion into New Zealand
10. Charm Sciences Announces New Sales/Business Manager
11. BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/14/2019)... ... March 14, 2019 , ... Xybion ... research organizations. It is a low code, GDPR/21 CFR Part 11-compliant digital ... technology-driven automated data capture and seamless data and information management. , ...
(Date:3/11/2019)... ... ... In this live webinar, the featured speakers will focus on the many attributes that ... how to use the information they have from the protocol and clinical trial knowledge, ... is properly designed and set up to ensure flawless execution. As clinical trial success ...
(Date:3/9/2019)... SEATTLE (PRWEB) , ... March ... ... source for unbiased college rankings and higher education planning, announced the release ... identifies the top programs in the nation based on curriculum quality, program ...
(Date:3/4/2019)... ... ... of current hot topics through free webinars presented by leading experts in pharma, biotech, medical ... today to save your place! Participate in the discussion and stay relevant in your field! ... , March 20 – Implementing BYOD Across Phase II and III Clinical Trials ...
Breaking Biology Technology:
(Date:3/9/2019)... ... March 08, 2019 , ... Ace ... product, Well-Mints™ resveratrol + ribose hard candy lozenges ( http://www.well-mints.com ). , Well-Mints™ ... naturally flavored hard candy base dusted with powdered sugar. , Well-Mints'™ patented technology ...
(Date:3/1/2019)... (PRWEB) , ... February 28, 2019 , ... Teresa Krabbe, ... der Isar of the Technical University Munich, has been awarded an xCELLigence Research Grant ... an improved oncolytic virus platform. , Oncolytic viruses represent an exciting new ...
(Date:2/22/2019)... ... 2019 , ... RoosterBio, Inc, a privately held regenerative medicine ... Frederick, MD after a year of rapid growth. , “Hundreds of researchers and ... products to streamline their product development efforts in the regenerative medicine field, resulting ...
Breaking Biology News(10 mins):